Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
MSL Visibility - How to SUCCEED in 2024
Summary
Tom Caravela welcomes Eleonora Goldberg to explore the evolving role of Medical Science Liaisons (MSLs) within organizations. They delve into the key attributes leaders seek in MSLs and share strategies for standing out and enhancing team performance. Essential skills for MSL effectiveness and methods for evaluating performance are discussed, alongside preparing for industry changes and maintaining positivity in 2024. Eleonora offers predictions and expresses optimism for the future of MSLs. The episode concludes with closing remarks, appreciation, and a reminder to subscribe and stay engaged.
My guest this week is Eleonora Goldberg, Vice President, Medical Affairs at Arrowhead Pharmaceuticals and we discuss MSL Visibility and how to succeed in 2024.
Eleonora shares….
π What is the VALUE of MSLs
π What leaders look for in MSLs
π How can MSLs separate themselves from their peers
π How might 2024 be different for MSLs
π What advice is there for dealing with uncertainty
Medical Science Liaisons, MSL effectiveness, MSL visibility, MSL strategies, Eleonora Goldberg
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
How to Start Presenting Like a Pro
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary